Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keeping Track: Opana ER Abuse Deterrence Claim Withdrawn; Third Neulasta Biosimilar Submitted; Keytruda Cleared In Head And Neck Cancer

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.


Related Content

Merck's Keytruda Gets Benefit Of Doubt, Despite Failing in Head & Neck
Immuno-Oncology Outlook: Getting To The Root Of Head And Neck Cancer
Opana Safety Review Will Set Tone For Opioid Regulation Under Trump
Heron's Sustol Faces Competition With Narrower Label Than Expected
Deal Worth Up to $464m Advances MEI Drug, Diversifies Helsinn's Portfolio
Opdivo's Failure In First-Line Lung Cancer Prompts Rethink On Trial Endpoints
Keeping Track: Approval Elusive For Biosimilar Neulasta; Valeant Gets A Nod And A No From FDA; Submissions From Amgen, Puma, Bristol
Keeping Track: More Bumps On The Abuse-Deterrent Opioid Road
Keeping Track: Alkermes' Aristada Approval; Bristol's Daklinza Submission; Lilly's Breakthrough
Keeping Track: FDA Clears Big Batch Of Products; 'Breakthrough' For Bristol HIV Drug


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts